Trial · NCT01289821
Adverse events110
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
21 to 40 of 110
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Alkaline phosphatase increased | Investigations | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 3 | 53 | 3 |
| other | Aspartate aminotransferase increased | Investigations | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 12 | 53 | 29 |
| other | Blood bilirubin increased | Investigations | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 9 | 53 | 15 |
| other | GGT increased | Investigations | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 8 | 53 | 17 |
| other | Lipase increased | Investigations | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 14 | 53 | 19 |
| other | Neutrophil count decreased | Investigations | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 35 | 53 | 88 |
| other | Investigations - Other, specify | Investigations | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 3 | 53 | 3 |
| other | Platelet count decreased | Investigations | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 25 | 53 | 61 |
| other | Serum amylase increased | Investigations | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 5 | 53 | 8 |
| other | White blood cell decreased | Investigations | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 6 | 53 | 8 |
| other | Weight loss | Investigations | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 5 | 53 | 7 |
| other | Allergic reaction | Immune system disorders | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 5 | 53 | 5 |
| other | Catheter related infection | Infections and infestations | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 3 | 53 | 5 |
| other | Infections and infestations - Other, specify | Infections and infestations | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 4 | 53 | 4 |
| other | Paronychia | Infections and infestations | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 3 | 53 | 3 |
| other | Upper respiratory infection | Infections and infestations | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 6 | 53 | 10 |
| other | Urinary tract infection | Infections and infestations | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 5 | 53 | 7 |
| other | Intestinal stoma site bleeding | Injury, poisoning and procedural complications | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 3 | 53 | 3 |
| other | Anorexia | Metabolism and nutrition disorders | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 21 | 53 | 41 |
| other | Hypocalcemia | Metabolism and nutrition disorders | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 6 | 53 | 7 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01289821/events?page=2